Treatment of end-stage cardiac failure with growth hormone

The results of recent studies suggest that human growth hormone (HDH) administration to patients with severe heart failure and cardiac cachexia has a beneficial effect that may be sustained after stopping HGH.

Saved in:
Bibliographic Details
Published inThe Lancet (British edition) Vol. 349; no. 9058; p. 1068
Main Authors O'Driscoll, JG, Green, DJ, Ireland, M, Kerr, D, Larbalestier, RI
Format Journal Article
LanguageEnglish
Published London Elsevier Ltd 12.04.1997
Lancet
Elsevier Limited
Subjects
Biological and medical sciences
Cachexia - complications
Cachexia - drug therapy
Cardiovascular disease
Drug therapy
Heart failure
Heart Failure - complications
Heart Failure - drug therapy
Hormones
Hormones. Endocrine system
Human Growth Hormone - therapeutic use
Humans
Male
Medical research
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Case study
Human
Heart failure
Chemotherapy
Cardiac performance
Treatment
Heart disease
Treatment efficiency
STH
Cardiovascular disease
Terminal stage
Cachexia
Online AccessGet full text

Cover

More Information
Summary:The results of recent studies suggest that human growth hormone (HDH) administration to patients with severe heart failure and cardiac cachexia has a beneficial effect that may be sustained after stopping HGH.
ISSN:0140-6736
1474-547X
DOI:10.1016/S0140-6736(05)62290-8